Evidence map›Paper›PMID 35799444›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2022

Broadening prime editing toolkits using RNA-Pol-II-driven engineered pegRNA.

Shisheng Huang, Zhenwu Zhang, Wanyu Tao, Yao Liu, Xiangyang Li, Xiaolong Wang, Javad Harati, Peng-Yuan Wang, Xingxu Huang, Chao-Po Lin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Animals : an open access journal from MDPI · 2025
    Review
  7. Recent advances in therapeutic gene-editing technologies.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Precise Gene Knock-In Tools with Minimized Risk of DSBs: A Trend for Gene Manipulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Shisheng HuangSchool of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China; Zhejiang Lab, Hangzhou, Zhejiang 311121, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Zhenwu ZhangSchool of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Wanyu TaoSchool of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Yao LiuKey Laboratory of Animal Genetics, Breeding and Reproduction of Shaanxi Province, College of Animal Science and Technology, Northwest A&F University, Yangling, 712100 Shaanxi, China.
Xiangyang LiSchool of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Xiaolong WangKey Laboratory of Animal Genetics, Breeding and Reproduction of Shaanxi Province, College of Animal Science and Technology, Northwest A&F University, Yangling, 712100 Shaanxi, China.
Javad HaratiNational Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran.
Peng-Yuan WangOujiang Laboratory, Wenzhou, Zhejiang, China.
Xingxu HuangSchool of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China; Zhejiang Lab, Hangzhou, Zhejiang 311121, China; Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou 310029, China. Electronic address: huangxx@shanghaitech.edu.cn.
Chao-Po LinSchool of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China. Electronic address: linzhb@shanghaitech.edu.cn.
ShanghaiTech University · CNNorthwest A&F University · CNPasteur Institute of Iran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prime editor is a versatile tool for targeted precise editing to generate point mutations, small insertions, or small deletions in eukaryotes. However, canonical PE3 system is less efficient, notably in primary cells or pluripotent stem cells. Here, we employed RNA polymerase II promoter instead of RNA polymerase III promoter, whose application is limited by specific DNA contexts, to produce Csy4-processed intronic prime editing guide RNAs (pegRNAs) and, together with other optimizations, achieved efficient targeting with poly(T)-containing pegRNAs, as well as combinatorial and conditional genetic editing. We also found simultaneous suppression of both DNA mismatch repair and DNA damage response could achieve efficient and accurate editing in human embryonic stem cells. These findings relieve the restrictions of RNA polymerase III (RNA-Pol-III)-based base editors and broadened the applications of prime editing.

Indexed as

CRISPR-Cas SystemsGene EditingRNA Polymerase IIHumansPromoter Regions, GeneticRNA, Guide, CRISPR-Cas SystemsRNA Polymerase IIIRNA, Guide, CRISPR-Cas SystemsRNA Polymerase IIRNA Polymerase IIICRISPRhuman pluripotent stem cellsp53 responseprime editor

Identifiers

PMID35799444
PMCPMC9481984
OpenAlexW4284965110

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.